At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 37 enrolled
Drug / intervention
cenegermin-bkbjdrug
Likely dose
cenegermin-bkbj 20 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)
In Brief
A Phase 4 clinical trial evaluating cenegermin-bkbj for Neurotrophic Keratitis. Completed, enrolled 37 participants across 5 sites.
Detailed Summary
This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurotrophic Keratitis
CountriesUnited States
CollaboratorsDompé, US, Inc.
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartSep 2020
Primary CompletionSep 2021
Study CompletionMar 2022
TodayJul 2026
First PostedJul 24, 2020
Enrollment StartSep 9, 2020
Primary CompletionSep 30, 2021
Study CompletionMar 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.9 years ago
Interventions
cenegermin-bkbjdrug
OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered as one drop in the affected eye(s), 6 times a day at 2-hour intervals for 8 weeks, in patients with Stage 1 neurotrophic keratitis.